CALIWAY BIOPHARMACEUTICALS CO L

Price Chart

Risk-Adjusted Performance

CALIWAY BIOPHARMACEUTICALS CO L (6919) Price Performance

CALIWAY BIOPHARMACEUTICALS CO L (6919) trades on TW in TWD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at TWD108.00, up 0.93% from the previous close.

Over the past year, 6919 has traded between a low of TWD60.50 and a high of TWD257.50. The stock has gained 78.5% over this period. It is currently 58.1% below its 52-week high.

CALIWAY BIOPHARMACEUTICALS CO L has a market capitalization of $166.53B.

About CALIWAY BIOPHARMACEUTICALS CO L

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.

Compare CALIWAY BIOPHARMACEUTICALS CO L

Side-by-side comparison against top Healthcare peers.